Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 9/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.38 |
| ▸ | BCL6 | P41182 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25818872 | 0.87 | NLRP3 (0.55) | NLRP3MAPTTP53RXFP1BCL6 | |
| SCHEMBL23952372 | 0.84 | NLRP3 (0.53) | NLRP3MAPTTP53RXFP1NTRK1 | |
| SCHEMBL23952218 | 0.83 | NLRP3 (0.74) | NLRP3MAPTTP53RXFP1NTRK1 | |
| SCHEMBL23952195 | 0.78 | NLRP3 (0.56) | NLRP3MAPTTP53RXFP1POLB | |
| SCHEMBL23952384 | 0.78 | NLRP3 (0.55) | NLRP3MAPTTP53RXFP1POLB | |
| SCHEMBL25818836 | 0.77 | NLRP3 (0.57) | NLRP3MAPTTP53RXFP1POLB | |
| SCHEMBL23952033 | 0.77 | NLRP3 (0.69) | NLRP3MAPTTP53RXFP1POLB | |
| SCHEMBL23952058 | 0.77 | NLRP3 (0.54) | NLRP3MAPTTP53RXFP1BCL6 | |
| SCHEMBL23952032 | 0.77 | NLRP3 (0.54) | NLRP3MAPTTP53RXFP1POLB | |
| SCHEMBL23952428 | 0.76 | NLRP3 (0.54) | NLRP3MAPTTP53RXFP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | NLRP3, NLRP1, IL1B | NLRP3 1/4885MAPT 1978/4885TP53 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.